Zinc, Copper, Vitamin E and Vitamin C: study protocols
30 study groups took Zinc together with Copper, Vitamin E and Vitamin C. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zinc
30 study groups in 22 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mg to 100 mg, 33% of 30 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 8 |
| 10 mg to 25 mg | 8 |
| 25 mg to 50 mg | 4 |
| 50 mg to 100 mg | 10 |
Dose per serving from research: Copper
23 study groups in 20 studies say how much Copper participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mcg to 1 mg and 1 mg to 2.5 mg, 39% of 23 study groups each.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 3 |
| 500 mcg to 1 mg | 9 |
| 1 mg to 2.5 mg | 9 |
| 2.5 mg to 5 mg | 2 |
Dose per serving from research: Vitamin E
14 study groups in 13 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 43% of 14 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg or less | 1 |
| 5 mg to 10 mg | 6 |
| 10 mg to 25 mg | 4 |
| 25 mg to 50 mg | 2 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 0 |
| over 250 mg | 1 |
Dose per serving from research: Vitamin C
29 study groups in 21 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 55% of 29 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg to 50 mg | 6 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 4 |
| 250 mg to 500 mg | 16 |
Commonly used together
28 of 30 study groups took Zinc, Copper, Vitamin E and Vitamin C with something else. Shown: what 3 or more different studies gave. The 10 most common of 18.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Iron | 13 |
| Vitamin A | 13 |
| Selenium | 11 |
| Beta-Carotene | 10 |
| Vitamin D | 10 |
| Iodine | 9 |
| Vitamin B12 | 9 |
| Niacin | 8 |
| Vitamin B6 | 8 |
| Folic Acid | 7 |
30 study groups
| Study | ||||||
|---|---|---|---|---|---|---|
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 2 mg | 400 IU | 500 mg | 2409 days | — |
| Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial 2007 · fortified milk · Children aged 1–3 years in a peri-urban settlement in north India | 7.8 mg | 270 mcg | 7.5 mg | 40.2 mg | 1 year | 316 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 2 mg | 400 IU | 500 mg | 8 years | — |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 20 mg | 2 mg | 8 mg | 50 mg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 30 mg | 2 mg | 10 mg | 100 mg | — | — |
| Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural South Africa 2009 · multiple micronutrients · children aged 6–24 months; three cohorts: HIV-infected children, HIV-uninfected children born to HIV-infected mothers, and HIV-uninfected children born to HIV-uninfected mothers | 10 mg | 600 mcg | 6 mg | 35 mg | 548 days | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 80 mg | 2 mg | 400 IU | 500 mg | 9 years | — |
| Effect of preventive supplementation with zinc and other micronutrients on non-malarial morbidity in Tanzanian pre-school children: a randomized trial 2012 · Multi-nutrients with zinc · Children aged 6–60 months with height-for-age z-score ≤−1.5 SD, in rural Tanzania | 10 mg | 340 mcg | — | — | — | 151 |
| Micronutrient fortified milk improves iron status, anemia and growth among children 1-4 years: a double masked, randomized, controlled trial 2010 · Micronutrient-fortified milk (MN group) · Children aged 1–4 years in India; many had anemia, iron deficiency, or growth faltering | 7.8 mg | 270 mcg | 7.5 mg | 40.2 mg | 1 year | 316 |
| Effect on longitudinal growth and anemia of zinc or multiple micronutrients added to vitamin A: a randomized controlled trial in children aged 6-24 months 2010 · Multiple micronutrients · Children enrolled at 6 months and followed to 24 months in rural South Africa; HIV-infected and HIV-uninfected children, both sexes | 10 mg | 600 mcg | 6 mg | 35 mg | 548 days | 126 |
| Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial 2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly | 8 mg | — | 30 mg | 320 mg | 12 weeks | 40 |
| TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD 2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye | 69.6 mg | 1.6 mg | 200 IU | 452 mg | 24 weeks | 37 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 22.5 mg | 1 mg | 30 mg | 180 mg | 1 year | 15 |
| The effects of antioxidant vitamin supplementation on expiratory flow rates at rest and during exercise 2015 · antioxidant vitamin supplementation (AVS) · healthy nonsmoking adults, 5 men and 5 women, consuming fewer than 5 servings of fruit and vegetables per day | 7.5 mg | 1 mg | 400 IU | 500 mg | 4 weeks | 10 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 2 (Vitalux AREDS) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 25 mg | 1 mg | 400 IU | 500 mg | — | 10 |
| The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7 2002 · antioxidants and zinc · Adults aged 55–80 years with early-to-late age-related macular degeneration | 80 mg | 2 mg | 400 IU | 500 mg | 5 years | — |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 12 mg | 1 mg | 15 mg | 85 mg | 165 days | 749 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 12 mg | 1 mg | 15 mg | 85 mg | — | 176 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 30 mg | 4 mg | 20 mg | 140 mg | 184 days | 75 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · PE+MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 30 mg | 4 mg | 20 mg | 140 mg | 184 days | 75 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men | 34.8 mg | — | — | 226 mg | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men | 69.6 mg | — | — | 452 mg | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 69.6 mg | — | 400 mg | 452 mg | 1 day | 15 |
| Multiple micronutrient supplementation improves micronutrient status in primary school children in Hai Phong City, Vietnam: a randomised controlled trial 2021 · intervention · Children aged 6–9 years, apparently healthy, in rural Hai Phong City, Vietnam; included undernourished, normal-weight, and overweight/obese children | 10 mg | 560 mcg | 5 mg | 30 mg | 22 weeks | 175 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 25 mg | 1 mg | 400 IU | 500 mg | — | 10 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 80 mg | 2 mg | 400 IU | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | 2 mg | 400 IU | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | — | 400 IU | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | — | 400 IU | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene and with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | — | 400 IU | 500 mg | 5 years | — |